All News

Psoriasis Severe legs sara

Systemic Steroids Seldom Flare Psoriasis

Jack Cush, MD

A tenet of drug management suggests that steroid use in psoriasis may be associated with rebound flares; well this has been challenged by a new observational trial showing that the risk of flares (and severe flares) of psoriasis flares were seldom triggered by systemic steroids - certainly much l

Read Article
steroids.prednisone.pills_.jpg

Mortality in Low Dose Prednisone

Eric Dein, MD

Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.

Read Article
covid vaccine needle vaccination

ACIP Recommendations for Pfizer Vaccine Candidate

Rachel Tate, DO

The CDC advisory panel, ACIP, has voted and declared that the first wave of vaccines should go to the front line healthcare workers and elderly residents in long term care facilities as part of Phase1a. The decision was not unanimous.

Read Article
podcast logo

RheumNow Podcast – Back Talk Listener Questions (12.04.20)

Jack Cush, MD

Dr Jack Cush takes questions from RheumNow listeners

Read Article
pregnant-776506__180.jpg

PIANO Study - Safety of Biologics in Pregnancy

Jack Cush, MD

The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.

Read Article
cost.healthcare.jpg

Colchicine Approval Took a Huge Toll on CMS

Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.

Read Article
pills-384846_640%20%281%29.jpg

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Richard Conway, MBBChBAO, PhD

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.

Read Article
Anakinra in Pediatric, Adult Still's Disease: Dr. Bella Mehta ( @bella_mehta) #ACR20 https://t.co/QiBEI11LY5 https://t.co/GTf7iUsfGt

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our latest article from Richard Conway ( @RichardPAConway) #ACR20 The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis https://t.co/VG1ah3Nq5c https://t.co/js3l527VHg

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets "RT @drdavidliew : Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/x7DLzZcn9o https://t.co/OmpTAorA13

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Ruderman ( @JointMD) discusses a new pathway - the use of deucravacitinib - to treat psoriatic arthritis at #ACR20. https://t.co/1uz47jKVPv https://t.co/1I5B14w9Ox

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @bella_mehta :Anakinra in #Stills disease - Dbl blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp. All pts reached ACR70 at wk 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90 ABS#1633 https://t.co/CCL6GONnvX https://t.co/KaoXBj3Azp

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway : Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/6fQNzqsvby

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Use MTX, starting oral but remember MTX tricks to maximize success. Folic acid, split dosing, SubQ all keys per Dr. O'Dell to maximize @RheumNow. https://t.co/OEAGi0bSZH https://t.co/aHsHF1Vm4l

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recs for RA: MTX is conditionally recommended with NORMAL LFTs and no advanced fibrosis. Role of HCQ for NALFD has been suggested at ACR, but not enough for mod-high disease activity @RheumNow. https://t.co/XswkhT1f66 https://t.co/bdngrnY9hc

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms #ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets "RT @DrMiniDey : RITAZAREM trial long-term f/u -RTX vs AZA after RTX-induced remission in ANCA -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 https://t.co/cKV7qM77og

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×